LBRX Stock: Price, Earnings History and SEC Filings
LB Pharmaceuticals Inc (LBRX) last traded at $39.70, down 1.12% on the latest session and up 3.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.71 against an analyst estimate of $-0.84, a miss of 103.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
LBRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-1.71 | $-0.84 | -103.57% |
| Mar 2026 | May 12, 2026 | $-0.67 | $-0.75 | +10.67% |
| Dec 2025 | Mar 26, 2026 | $-0.45 | $-0.45 | +0.00% |
| Sep 2025 | Nov 6, 2025 | $-0.61 | $-0.57 | -7.02% |
LBRX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How LBRX reacts to earnings
Across its last 4 earnings releases, LBRX moved 3.0% on average the next session, in either direction. It rose after 1 of 4 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | Before open | -1.13% |
| 2026-05-12 | After close | +3.79% |
| 2026-03-26 | After close | -2.81% |
| 2025-11-06 | Before open | -4.26% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
Latest SEC filings for LBRX
- 424B3 · Sep 15, 2026
- 8-K · Sep 15, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 424B3 · Sep 3, 2026
- 8-K · Sep 3, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 424B3 · Aug 11, 2026
- 10-Q · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 424B3 · Jul 29, 2026
- 8-K · Jul 29, 2026Material agreement, Unregistered share sale, Regulation FD disclosure
- 424B3 · Jul 22, 2026
Insider filing activity
LBRX insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
LBRX news
- Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial dataOct 28, 2026 · finance.yahoo.com
- LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in SchizophreniaOct 28, 2026 · marketbeat.com
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc (LBRX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.